Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

UPDATE: e-Therapeutics gets good indications from cancer treatment trial

Treatment was well-tolerated and showed signs of halting tumour progression at higher doses.

--adds broker comment, share price--

e-Therapeutics (LON:ETX) today reported positive interim results from the UK phase 1a trial of cancer treatment ETS2101 (dexanabinol) in a variety of solid tumours.

The new treatment was well tolerated at all six dose escalations with no serious diverse events attributed to the drug, while there was also early signs of the possible halting of tumour progression.

In an earlier cohort, a single incident of dose-limiting fatigue was noted, but has not been repeated in any other patient to date, e-Therapeutics added.

UK clinical investigators now intend to enrol further patients at higher dose levels and to continue to escalate until a maximum tolerated dose has been established.

The possibility that tumours might be affected by higher doses of ETS2101 will be explored further in particular.

Professor Ruth Plummer, the trial’s principal investigator said: “In the last two cohorts (15mg/kg and 22mg/kg), we have seen a number of patients who have come onto the study with advanced progressive disease and have stayed on study in some cases for over five months.

"This suggests that the compound may be halting tumour progression as measured by RECIST criteria.

"We are excited by this initial observation, and are very keen to continue to escalate the dose to confirm this and explore if further possible anti-tumour effects will be found.”

Steve Self, e-Therapeutics’ development director, added: “The latest findings from ETS2101 are encouraging. We will continue to dose escalate to find the maximum tolerated dose and further explore the observations of possible activity in cancer patients that we have seen in the most recent two cohorts.

“These data, along with the US phase I data, are important in helping us to refine the next steps with this compound.”

Panmure Gordon noted that while a maximum tolerated dose has not been established, the comments regarding the halting of  tumour progression were above and beyond what it had expected, although the dose escalation to even higher doses is critical. 

The broker added that the patients recruited in this trial were very sick with few therapeutic options available to them, so to achieve a 'partial response', ie shrinking of the tumour significantly more than 30%, was a welcome outcome. 

"With 17p of cash per share and a novel platform underpinning the investment thesis, we view today’s news as a strong conduit to a period of outperformance", it said. 

"The fact that patients who had ran out of all therapeutic options managed to get some extra time in this life as a result of ETS2101 was a significant achievement for the company’s first shot at goal and underlines the value of the platform.

"Beyond the immediate pipeline, the main attraction of this operation is its technology platform that could revolutionise how the pharmaceutical industry conducts drug development. 

Panmure has a 70p price target, based solely on the prospects for ETS 2101 (Dexanabinol) and a 'buy' stance.

Shares rose 7% to 23.5p.

View full ETX profile View Profile

e-Therapeutics plc Timeline

CN Video
March 28 2018

Related Articles

June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use